{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:59:18Z","timestamp":1785113958079,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA215312"],"award-info":[{"award-number":["K08CA215312"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["1017184"],"award-info":[{"award-number":["1017184"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pathogenic germline\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer (BC) is the most common cancer in LFS females. Here, we perform a multimodal analysis, comparing LFS-BC with sporadic premenopausal breast cancer which shows that nearly all LFS-BC undergo biallelic loss of\n                    <jats:italic>TP53<\/jats:italic>\n                    , with no recurrent oncogenic variants except\n                    <jats:italic>ERBB2<\/jats:italic>\n                    (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibit a high burden of short amplified aneuploid segments. Pro-apoptotic p53 target genes\n                    <jats:italic>BAX<\/jats:italic>\n                    and\n                    <jats:italic>TP53I3<\/jats:italic>\n                    fail to be up-regulated in LFS-BC unlike in sporadic BC compared to normal breast tissue. LFS-BC has lower CD8\u2009+\u2009T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from in situ to invasive BC is marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-73163-4","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:59:45Z","timestamp":1779346785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers"],"prefix":"10.1038","volume":"17","author":[{"given":"Nabamita","family":"Boruah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyta","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hausler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh N.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8078-808X","authenticated-orcid":false,"given":"Madeline","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvathi","family":"Raghavakaimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliha","family":"Tayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana","family":"Narasimhamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-9669","authenticated-orcid":false,"given":"Peter","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7132-290X","authenticated-orcid":false,"given":"Jinae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-4064","authenticated-orcid":false,"given":"Miguel","family":"Lopez de Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4833","authenticated-orcid":false,"given":"Kurt A.","family":"Schalper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari B.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupma","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-6387","authenticated-orcid":false,"given":"Arnold J.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-8793","authenticated-orcid":false,"given":"Benjamin D.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-4202","authenticated-orcid":false,"given":"Kara N.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"73163_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"73163_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1947601911408889","volume":"2","author":"N Rivlin","year":"2011","unstructured":"Rivlin, N., Brosh, R., Oren, M. & Rotter, V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466\u2013474 (2011).","journal-title":"Genes Cancer"},{"key":"73163_CR3","first-page":"6788","volume":"60","author":"A Sigal","year":"2000","unstructured":"Sigal, A. & Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788\u20136793 (2000).","journal-title":"Cancer Res."},{"key":"73163_CR4","first-page":"100242","volume":"5","author":"KC de Andrade","year":"2023","unstructured":"de Andrade, K. C. et al. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants. HGG Adv. 5, 100242 (2023).","journal-title":"HGG Adv."},{"key":"73163_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jmg.2008.058958","volume":"46","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez, K. D. et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J. Med. Genet. 46, 689\u2013693 (2009).","journal-title":"J. Med. Genet."},{"key":"73163_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","volume":"361","author":"F Lalloo","year":"2003","unstructured":"Lalloo, F. et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. The Lancet 361, 1101\u20131102 (2003).","journal-title":"The Lancet"},{"key":"73163_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1947601911413466","volume":"2","author":"D Malkin","year":"2011","unstructured":"Malkin, D. Li-Fraumeni syndrome. Genes Cancer 2, 475\u2013484 (2011).","journal-title":"Genes Cancer"},{"key":"73163_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","volume":"133","author":"S Masciari","year":"2012","unstructured":"Masciari, S. et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res. Treat. 133, 1125\u20131130 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"73163_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/cjp2.133","volume":"5","author":"K Packwood","year":"2019","unstructured":"Packwood, K. et al. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the cohort study of TP53 carrier early onset breast cancer (COPE study). J. Pathol. Clin. Res. 5, 189\u2013198 (2019).","journal-title":"J. Pathol. Clin. Res."},{"key":"73163_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.onc.1202033","volume":"17","author":"JM Birch","year":"1998","unstructured":"Birch, J. M. et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17, 1061\u20131068 (1998).","journal-title":"Oncogene"},{"key":"73163_CR11","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.3390\/cancers12123762","volume":"12","author":"DG Evans","year":"2020","unstructured":"Evans, D. G., Woodward, E. R., Bajalica-Lagercrantz, S., Oliveira, C. & Frebourg, T. Germline TP53 testing in breast cancers: why, when and how? Cancers 12, 3762 (2020).","journal-title":"Cancers"},{"key":"73163_CR12","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/cncr.31551","volume":"124","author":"KA Cronin","year":"2018","unstructured":"Cronin, K. A. et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124, 2785\u20132800 (2018).","journal-title":"Cancer"},{"key":"73163_CR13","doi-asserted-by":"publisher","unstructured":"DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A. & Siegel, R. L. Cancer statistics for African Americans, 2019. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21555 (2019).","DOI":"10.3322\/caac.21555"},{"key":"73163_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41379-020-0610-4","volume":"34","author":"MG Kuba","year":"2021","unstructured":"Kuba, M. G. et al. Histopathologic features of breast cancer in Li-Fraumeni syndrome. Mod. Pathol. 34, 542\u2013548 (2021).","journal-title":"Mod. Pathol."},{"key":"73163_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jmg.2010.078113","volume":"47","author":"JRF Wilson","year":"2010","unstructured":"Wilson, J. R. F. et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J. Med. Genet. 47, 771\u2013774 (2010).","journal-title":"J. Med. Genet."},{"key":"73163_CR16","first-page":"67","volume":"71","author":"FP O\u2019Malley","year":"1994","unstructured":"O\u2019Malley, F. P. et al. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab. Investig. J. Tech. Methods Pathol. 71, 67\u201372 (1994).","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"73163_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35727-y","volume":"14","author":"N Light","year":"2023","unstructured":"Light, N. et al. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nat. Commun. 14, 77 (2023).","journal-title":"Nat. Commun."},{"key":"73163_CR18","doi-asserted-by":"publisher","first-page":"762651","DOI":"10.3389\/fcell.2021.762651","volume":"9","author":"D Shi","year":"2021","unstructured":"Shi, D. & Jiang, P. A different facet of p53 function: regulation of immunity and inflammation during tumor development. Front. Cell Dev. Biol. 9, 762651 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"73163_CR19","doi-asserted-by":"publisher","first-page":"1057302","DOI":"10.3389\/fgene.2022.1057302","volume":"13","author":"Y Tao","year":"2022","unstructured":"Tao, Y. et al. TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: a multi-omics study. Front. Genet. 13, 1057302 (2022).","journal-title":"Front. Genet."},{"key":"73163_CR20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic Hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769 (2018).","journal-title":"Cell"},{"key":"73163_CR21","doi-asserted-by":"publisher","first-page":"e1356142","DOI":"10.1080\/2162402X.2017.1356142","volume":"6","author":"DA Quigley","year":"2017","unstructured":"Quigley, D. A. et al. Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. Oncoimmunology 6, e1356142 (2017).","journal-title":"Oncoimmunology"},{"key":"73163_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"K-L Huang","year":"2018","unstructured":"Huang, K.-L. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355\u2013370.e14 (2018).","journal-title":"Cell"},{"key":"73163_CR23","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1038\/onc.2016.502","volume":"36","author":"M Fischer","year":"2017","unstructured":"Fischer, M. Census and evaluation of p53 target genes. Oncogene 36, 3943\u20133956 (2017).","journal-title":"Oncogene"},{"key":"73163_CR24","first-page":"317","volume":"13","author":"A Zgura","year":"2018","unstructured":"Zgura, A., Galesa, L., Bratila, E. & Anghel, R. Relationship between tumor infiltrating lymphocytes and progression in breast cancer. Maedica 13, 317\u2013320 (2018).","journal-title":"Maedica"},{"key":"73163_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05032-8","volume":"9","author":"SN Gettinger","year":"2018","unstructured":"Gettinger, S. N. et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat. Commun. 9, 3196 (2018).","journal-title":"Nat. Commun."},{"key":"73163_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41586-022-05082-5","volume":"608","author":"T Baslan","year":"2022","unstructured":"Baslan, T. et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature 608, 795\u2013802 (2022).","journal-title":"Nature"},{"key":"73163_CR27","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.3390\/cells11193097","volume":"11","author":"L Yedidia-Aryeh","year":"2022","unstructured":"Yedidia-Aryeh, L. & Goldberg, M. The interplay between the cellular response to DNA double-strand breaks and estrogen. Cells 11, 3097 (2022).","journal-title":"Cells"},{"key":"73163_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41586-023-06057-w","volume":"618","author":"JJ-K Lee","year":"2023","unstructured":"Lee, J. J.-K. et al. ER\u03b1-associated translocations underlie oncogene amplifications in breast cancer. Nature 618, 1024\u20131032 (2023).","journal-title":"Nature"},{"key":"73163_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00426-w","volume":"8","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer 8, 62 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"73163_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-022-00447-3","volume":"17","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1\/2 mutations. Hum. Genom. 17, 2 (2023).","journal-title":"Hum. Genom."},{"key":"73163_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).","journal-title":"Science"},{"key":"73163_CR32","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2017.2140","volume":"3","author":"T Karn","year":"2017","unstructured":"Karn, T. et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 3, 1707\u20131711 (2017).","journal-title":"JAMA Oncol."},{"key":"73163_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00352-3","volume":"7","author":"I Zerdes","year":"2021","unstructured":"Zerdes, I. et al. Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. NPJ Breast Cancer 7, 144 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"73163_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/science.adh8697","volume":"384","author":"KE Houlahan","year":"2024","unstructured":"Houlahan, K. E. et al. Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Science 384, eadh8697 (2024).","journal-title":"Science"},{"key":"73163_CR35","doi-asserted-by":"publisher","first-page":"759154","DOI":"10.3389\/fcell.2021.759154","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Hao, R., Guo, Q., Zhang, S. & Wang, X. TP53 mutation infers a poor prognosis and is correlated to immunocytes infiltration in breast cancer. Front. Cell Dev. Biol. 9, 759154 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"73163_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.01.016","volume":"168","author":"A Schiza","year":"2022","unstructured":"Schiza, A. et al. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. Eur. J. Cancer 168, 128\u2013137 (2022).","journal-title":"Eur. J. Cancer"},{"key":"73163_CR37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar, C. R. et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 7, 1098\u20131115 (2017).","journal-title":"Cancer Discov."},{"key":"73163_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/djy085","volume":"110","author":"MM Hoppe","year":"2018","unstructured":"Hoppe, M. M., Sundar, R., Tan, D. S. P. & Jeyasekharan, A. D. Biomarkers for homologous recombination deficiency in cancer. J. Natl. Cancer Inst. 110, 704\u2013713 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"73163_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41586-022-04696-z","volume":"606","author":"D Hoyos","year":"2022","unstructured":"Hoyos, D. et al. Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature 606, 172\u2013179 (2022).","journal-title":"Nature"},{"key":"73163_CR40","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","volume":"10","author":"S Kumar","year":"2023","unstructured":"Kumar, S. et al. Targeting PD-1\/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes Dis. 10, 1318\u20131350 (2023).","journal-title":"Genes Dis."},{"key":"73163_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41591-020-1133-8","volume":"27","author":"J Park","year":"2021","unstructured":"Park, J. et al. Exome-wide evaluation of rare coding variants using electronic health records identifies new gene-phenotype associations. Nat. Med. 27, 66\u201372 (2021).","journal-title":"Nat. Med."},{"key":"73163_CR42","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/jpm12121974","volume":"12","author":"A Verma","year":"2022","unstructured":"Verma, A. et al. The Penn Medicine BioBank: towards a genomics-enabled learning healthcare system to accelerate precision medicine in a diverse population. J. Pers. Med. 12, 1974 (2022).","journal-title":"J. Pers. Med."},{"key":"73163_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 144, 545\u2013563 (2020).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"73163_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","volume":"147","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\u2013College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 147, 993\u20131000 (2023).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"73163_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00388-9","volume":"8","author":"KN Maxwell","year":"2017","unstructured":"Maxwell, K. N. et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 8, 319 (2017).","journal-title":"Nat. Commun."},{"key":"73163_CR46","doi-asserted-by":"crossref","unstructured":"Clark, D. F. et al. Identification and confirmation of potentially actionable germline mutations in tumor-only genomic sequencing. JCO Precis. Oncol. 3, 1\u201311 (2019).","DOI":"10.1200\/PO.19.00076"},{"key":"73163_CR47","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"73163_CR48","doi-asserted-by":"publisher","unstructured":"Poplin, R., Ruano-Rubio, V. & DePristo, M. Scaling accurate genetic variant discovery to tens of thousands of samples. Preprint at https:\/\/doi.org\/10.1101\/201178 (2017).","DOI":"10.1101\/201178"},{"key":"73163_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"73163_CR50","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"73163_CR51","doi-asserted-by":"publisher","unstructured":"Pluta, J. et al. HRDex: a tool for deriving homologous recombination deficiency (HRD) scores from whole exome sequencing data. Preprint at https:\/\/doi.org\/10.1101\/2022.09.08.506670 (2022).","DOI":"10.1101\/2022.09.08.506670"},{"key":"73163_CR52","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"73163_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"73163_CR54","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 1, 1\u201316 (2017)."},{"key":"73163_CR55","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu, B. et al. MSI sensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015\u20131016 (2014).","journal-title":"Bioinformatics"},{"key":"73163_CR56","unstructured":"Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science 376, abl9283 (2022)."},{"key":"73163_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"73163_CR58","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"73163_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"73163_CR60","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1093\/bioinformatics\/btm369","volume":"23","author":"A Subramanian","year":"2007","unstructured":"Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J. P. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics 23, 3251\u20133253 (2007).","journal-title":"Bioinformatics"},{"key":"73163_CR61","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"73163_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"73163_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"73163_CR64","doi-asserted-by":"publisher","unstructured":"Fortuno, C. et al. Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants. Hum. Mutat. https:\/\/doi.org\/10.1002\/humu.24152 (2020).","DOI":"10.1002\/humu.24152"},{"key":"73163_CR65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"73163_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"73163_CR67","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/curroncol30020102","volume":"30","author":"JCA Moreno","year":"2023","unstructured":"Moreno, J. C. A. et al. Prognostic significance of p53 and p63 in diffuse large B-cell lymphoma: a single-institution experience. Curr. Oncol. 30, 1314\u20131331 (2023).","journal-title":"Curr. Oncol."},{"key":"73163_CR68","doi-asserted-by":"publisher","first-page":"583333","DOI":"10.3389\/fphys.2020.583333","volume":"11","author":"H Mi","year":"2020","unstructured":"Mi, H. et al. Digital pathology analysis quantifies spatial heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 immune markers in triple-negative breast cancer. Front. Physiol. 11, 583333 (2020).","journal-title":"Front. Physiol."},{"key":"73163_CR69","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","volume":"25","author":"I Datar","year":"2019","unstructured":"Datar, I. et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25, 4663\u20134673 (2019).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"73163_CR70","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1078-0432.CCR-21-2649","volume":"28","author":"N Gavrielatou","year":"2022","unstructured":"Gavrielatou, N. et al. Association of PD-1\/PD-L1 co-location with immunotherapy outcomes in non-small cell lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 28, 360\u2013367 (2022).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"73163_CR71","doi-asserted-by":"crossref","unstructured":"Schalper, K. A. et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J. Natl. Cancer Inst. 107, dju435 (2015).","DOI":"10.1093\/jnci\/dju435"},{"key":"73163_CR72","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/1078-0432.CCR-23-2457","volume":"30","author":"M Lopez de Rodas","year":"2024","unstructured":"Lopez de Rodas, M. et al. Objective analysis and clinical significance of the spatial tumor-infiltrating lymphocyte patterns in non-small cell lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 30, 998\u20131008 (2024).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73163-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:02:40Z","timestamp":1785110560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73163-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73163"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73163-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.A.S. reports fees for consultant services, advisor or speaker from Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, Takeda, Torque\/Repertoire Therapeutics, CSRlife, Agenus, Genmab, Sanofi, Parthenon Therapeutics, Bristol-Myers Squibb, Roche, Molecular Templates, Merck, PeerView, PER and Forefront Collaborative. A.J.L. is the founder and shareholder of PMV Pharma, a biotech company that works on a reactivator of mutant p53. B.D.G. has received honoraria for speaking engagements from Merck, Bristol Myers Squibb, and Chugai Pharmaceuticals; has received research funding from Bristol Myers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies, and ROME Therapeutics, of which he is a co-founder. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7300"}}